Related Experiment Video
Updated: Aug 24, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Carboplatin and docetaxel in advanced non-small-cell lung cancer: results of a multicenter phase II study
Sakkaraiappan Ramalingam1, Tracy W Dobbs, Avi I Einzig
1Division of Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Background:
To evaluate the efficacy of carboplatin and docetaxel combination in patients with advanced non-small-cell lung cancer.
Methods:
In a phase II study, patients with inoperable stage IIIB or stage IV non-small-cell lung cancer (ECOG performance status of 0 or 1) were treated with the combination of carboplatin AUC 5 mg/ml.min and docetaxel 80 mg/m2 administered once every 3 weeks.
Results:
A total of 45 patients were accrued to the study. The median age was 62 years and adenocarcinoma was the most common histology. Patients received a median of four cycles of chemotherapy. The objective response rate was 29% with a median survival of 11.9 months among evaluable patients. The 1-year survival rate was 47%. Febrile neutropenia (17%) was the most common hematological toxicity associated with the regimen whereas grade 3 fatigue (4%) was the major nonhematological toxicity.
Conclusions:
The combination of carboplatin plus docetaxel is well tolerated and is effective for the treatment of patients with previously untreated advanced or metastatic non-small-cell lung cancer.
